



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Matthew J. During
Application No: 09/491,896
Filing Date: January 24, 2000
Entitled: NMDA Vaccine for the Treatment of Epilepsy
Atty. Docket No: 102194-6

Group Art Unit: 1647
Examiner: B. Bunner

RECEIVED

FEB 05 2002

TECH CENTER 1600/2900

RECEIVED
FEB 01 2002
TECH CENTER 1600/2900

15/B
M.G.J
2/5/02

Certificate of Mailing (37 C.F.R. 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service Post Office as first class mail in an envelope addressed to: Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

1/28/02	By:	
Date of Signature and Mail Deposit		Jasbir Sagoo Reg. No: P-51177

AMENDMENT PURSUANT TO 37 CFR §1.114

BOX AF
Commissioner for Patents
Washington, DC 20231

Dear Sir:

This Amendment and Response is submitted in response to the final Office Action dated August 27, 2001. Please amend the above-referenced patent application as follows:

In the Specification

At page 1 under the heading "Related Case Information," please cancel:

"The present invention claims priority to U.S. Provisional Application No. 60/116,748, filed January 22, 1999 entitled: Vaccine-Mediated Treatment of Neurological Disorders and U.S. Provisional Application No. 60/127,142, filed March 31, 1999 entitled: Vaccine-Mediated Treatment of Neurological Disorders." and replace with